Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This trial is an extension to ENSURE, a study of erlotinib versus gemcitabine/cisplatin
combination chemotherapy as the first-line treatment for patients with non-small-cell lung
cancer (NSCLC) with mutations in the tyrosine kinase domain of EGFR.
This study is designed to examine the efficacy of erlotinib versus gemcitabine/cisplatin as a
second-line treatment in NSCLC patients from the ENSURE trial (NCT01342965). Patients
previously treated with gemcitabine/cisplatin will be given erlotinib daily until disease
progression or unacceptable toxicity occurs. Patients previously treated with erlotinib will
be given cisplatin on Day 1 and gemcitabine on Days 1 and 8 of 3-week chemotherapy cycles
until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first).